Company Overview and News

 
Introduction of new taxes could further impact property sector, says TA Securities

2018-10-15 theedgemarkets
KUALA LUMPUR (Oct 15): Any introduction of new taxes — such as the inheritance tax and capital gain tax — could weigh on house buyers and investor sentiment, further impacting the property sector which has already been plagued by affordability and strict lending issues, according to TA Securities.
5249 5062 GLOCF

 
Sime Darby Property seen targeting more disposals

2018-10-02 theedgemarkets
Sime Darby Property Bhd (Oct 1, RM1.15) Initiate coverage at market perform with a target price (TP) of RM1.25: Sime Darby Property Bhd is a township developer with over 40 years of experience and a vast land bank of 20,600 acres (8,336.52ha) with an estimated remaining gross development value (GDV) of RM137 billion, but this does not include the option land agreements with its sister companies of another 20,600 acres which we estimate have a potential GDV of RM68 billion.
5249 8664

 
Little-known SBC Corp attracts heavyweight investors

2018-09-26 theedgemarkets
SBC Corp Bhd may not be a heavyweight property developer in terms of size and profitability but it has several recognisable and prominent names listed as its minority shareholders.
6769 3611 5249 7096 2755 8648 3514 6521 8044 BSMAF 1818

 
Trading ideas: AirAsia, IOI Properties, Bumi Armada, CCM

2018-09-12 thestar.com.my
KUALA LUMPUR: AirAsia Bhd , IOI Properties Group Bhd , Bumi Armada Bhd and Chemical Company of Malaysia Bhd (CCM) are among the stocks to watch on Wednesday, according to JF Apex Research.
5249 BRDBF 5210

 
KLCI seen tracking global markets, move between 1,790-1,800

2018-09-11 theedgemarkets
KUALA LUMPUR (Sept 12): The FBM KLCI is seen trading range bound today, and move between the 1,790 and 1,800-levels, in line with the overnight gains at most global markets.
5249 0145 5049 BRDBF 5210 0075

 
IOI Properties, AirAsia, Bumi Armada, Country View, CCM, Sunsuria, TDM, Serba Dinamik, TFP and Mexter

2018-09-07 theedgemarkets
KUALA LUMPUR (July 5): Based on corporate announcements and news flow today, companies in focus on Wednesday (Sept 12) may include: IOI Properties Group Bhd, AirAsia Group Bhd, Bumi Armada Bhd, Country View Bhd, Chemical Company of Malaysia Bhd, Sunsuria Bhd, TDM Bhd, Serba Dinamik Holdings Bhd, TFP Solutions Bhd and Mexter Technology Bhd.
5249 0145 5049 BRDBF BSMAF 5210 0075 1818

 
IOI Properties' subsidiary makes RM1.2b sukuk issuance

2018-09-07 theedgemarkets
KUALA LUMPUR (Sept 7): IOI Properties Group Bhd said its unit Fortune Premiere Sdn Bhd had today made its third Sukuk Murabahah issuance of RM1.2 billion to finance the group's capital requirements and refinance existing borrowings.
5249 BSMAF 1818

 
IOI Properties 4Q profit down 21.3% to RM264.99m

2018-08-28 theedgemarkets
KUALA LUMPUR: IOI Properties Group Bhd’s fourth-quarter (4Q) net profit dropped 21.3% year-on-year to RM264.99 million from RM336.64 million, due to a reduced contribution from its overseas property projects.
5249

 
Trading ideas: Vertice, Daiman, Padini, Matrix Concept, IOI Properties

2018-08-28 thestar.com.my
KUALA LUMPUR: Vertice Bhd, Daiman Development Bhd , Padini Holdings Bhd , Matrix Concepts Holdings Bhd and IOI Properties Group Bhd are among the stocks to watch, according to JF Apex Research.
5249 9385 7052 5236 5355

 
IOI Properties cautiously optimistic on its outlook

2018-08-28 thestar.com.my
Chinese demand: IOI Properties expects contribution from overseas - led by projects in China - to rebound in the coming quarters.
5249 BSMAF 1818

 
Daiman Development, Gamuda, Taliworks, Top Glove, Matrix Concept, Vertice, BIMB, IOI Properties, Utusan, WCT and Watta

2018-08-27 theedgemarkets
KUALA LUMPUR (Aug 27): Based on corporate announcements and news flow today, stocks in focus on Tuesday (Aug 28) may include Daiman Development Bhd, Gamuda Bhd, Taliworks Corp Bhd, Top Glove Corp Bhd, Matrix Concepts Holdings Bhd, Vertice Bhd, BIMB Holdings Bhd, IOI Properties Group Bhd, Utusan Melayu (Malaysia) Bhd, WCT Holdings Bhd and Watta Holding Bhd.
7240 7113 TPGVF 9679 7226 5355 TGLVY 5249 5754 5258 5236 BSMAF 1818

 
IOI Properties 4Q profit down 21.3% on lower contribution from overseas projects

2018-08-27 theedgemarkets
KUALA LUMPUR (Aug 27): IOI Properties Group Bhd's fourth quarter net profit dropped 21.3% year-on-year to RM264.99 million from RM336.64 million, due to reduced contribution from its overseas property projects.
5249 BSMAF 1818

 
IOI Properties FY18 net profit falls to RM783.63m

2018-08-27 malaymail
KUALA LUMPUR, Aug 27 — IOI Properties Group Bhd’s net profit fell to RM783.63 million for the financial year ended June 30, 2018 (FY18) from RM920.87 million in the previous year.
5249 BSMAF 1818

 
KLCI dips 0.27% on profit taking, Tenaga & Genting weigh

2018-08-01 theedgemarkets
KUALA LUMPUR (Aug 1): The FBM KLCI dipped 0.27% in early trade today on some mild profit taking against the backdrop of higher regional markets, dragged by losses including at Tenaga Nasional Bhd and Genting Bhd.
HLFBF 5249 5347 TNABY UPBMF 1082 TNABF 5246 2089 GEBHF

 
IOI Properties may trend higher, says RHB Retail Research

2018-07-31 theedgemarkets
KUALA LUMPUR (July 31): RHB Retail Research said IOI Properties Group Bhd may trend higher after it formed a long white candle and breached above the RM1.80 threshold.
5249

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...